BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 36474403)

  • 21. Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype.
    Dashti NK; Wehrs RN; Thomas BC; Nair A; Davila J; Buckner JC; Martinez AP; Sukov WR; Halling KC; Howe BM; Folpe AL
    Histopathology; 2018 Sep; 73(3):514-520. PubMed ID: 29758589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pediatric spindle cell/sclerosing rhabdomyosarcoma with
    Fang Z; Duan C; Wang S; Fu L; Yang P; Yu T; Deel MD; Lau LMS; Ma X; Ni X; Su Y
    Transl Pediatr; 2024 Jan; 13(1):178-191. PubMed ID: 38323177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelioid and spindle rhabdomyosarcoma with TFCP2 rearrangement in abdominal wall: a distinctive entity with poor prognosis.
    Li Y; Li D; Wang J; Tang J
    Diagn Pathol; 2023 Mar; 18(1):41. PubMed ID: 36998041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraosseous Spindle Cell/Epithelioid Rhabdomyosarcoma with
    Valério E; Furtado Costa JL; Perez Fraile NM; Credidio CH; Taveira Garcia MR; Neto CS; Costa FD
    Int J Surg Pathol; 2023 Aug; 31(5):861-865. PubMed ID: 36474403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases.
    Chrisinger JSA; Wehrli B; Dickson BC; Fasih S; Hirbe AC; Shultz DB; Zadeh G; Gupta AA; Demicco EG
    Virchows Arch; 2020 Nov; 477(5):725-732. PubMed ID: 32556562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological features of rhabdomyosarcoma with novel FET::TFCP2 and TIMP3::ALK fusion: report of two cases and literature review.
    Duan FL; Yang H; Gong X; Zuo Z; Qin S; Ji J; Zhou C; Dai J; Guo P; Liu Y
    Histopathology; 2023 Feb; 82(3):478-484. PubMed ID: 36350070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epithelioid and spindle cell rhabdomyosarcoma with EWSR1::TFCP2 fusion mimicking metastatic lung cancer: A case report and literature review.
    Haug L; Doll J; Appenzeller S; Kunzmann V; Rosenwald A; Maurus K; Gerhard-Hartmann E
    Pathol Res Pract; 2023 Sep; 249():154779. PubMed ID: 37633005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spindle cell rhabdomyosarcomas: With TFCP2 rearrangements, and novel EWSR1::ZBTB41 and PLOD2::RBM6 gene fusions. A study of five cases and review of the literature.
    Bradová M; Mosaieby E; Michal M; Vaněček T; Ing SK; Grossmann P; Koshyk O; Kinkor Z; Laciok Š; Nemcová A; Straka Ľ; Farkas M; Michal M; Švajdler M
    Histopathology; 2024 Apr; 84(5):776-793. PubMed ID: 38114270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelioid Rhabdomyosarcoma: Report of a Cutaneous Case and Literature Review of a Recently Described Variant of Rhabdomyosarcoma.
    Valério E; Almeida GC; Neotti T; Nascimento AG; Bezerra SM; Costa FD
    Am J Dermatopathol; 2020 Apr; 42(4):275-279. PubMed ID: 31688007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rhabdomyosarcoma with TFCP2 Rearrangement or Typical Co-expression of AE1/AE3 and ALK: Report of Three New Cases in the Head and Neck Region and Literature Review.
    Gallagher KPD; Roza ALOC; Tager EMJR; Mariz BALA; Soares CD; Rocha AC; Abrahão AC; Romañach MJ; Carlos R; Hunter KD; Lopes MA; Vargas PA; Santos-Silva AR
    Head Neck Pathol; 2023 Jun; 17(2):546-561. PubMed ID: 36374445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone and soft tissue tumors: clinicoradiologic-pathologic molecular-genetic correlation of novel fusion spindled, targetable-ovoid, giant-cell-rich, and round cell sarcomas.
    Fanburg-Smith JC; Smith JD; Flemming DJ
    Skeletal Radiol; 2023 Mar; 52(3):517-540. PubMed ID: 36542130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraosseous Spindle Cell Rhabdomyosarcoma with
    Smith BF; Doung YC; Beckett B; Corless CL; Davis LE; Davis JL
    Cancer Invest; 2023 Sep; 41(8):704-712. PubMed ID: 37668330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular profile of head and neck rhabdomyosarcomas: A systematic review and meta-analysis.
    Gallagher KPD; van Heerden W; Said-Al-Naief N; Carlos R; Arboleda LPA; Rodrigues-Fernandes CI; Araújo ALD; Fonseca FP; Pontes HAR; Innocentini LMAR; Romañach MJ; Vargas PA; Lopes MA; Santos-Silva AR; Khurram SA
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Sep; 134(3):354-366. PubMed ID: 35840496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The current landscape of rhabdomyosarcomas: an update.
    Leiner J; Le Loarer F
    Virchows Arch; 2020 Jan; 476(1):97-108. PubMed ID: 31696361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Integrative Morphologic and Molecular Approach for Diagnosis and Subclassification of Rhabdomyosarcoma.
    Fan R; Parham DM; Wang LL
    Arch Pathol Lab Med; 2022 Aug; 146(8):953-959. PubMed ID: 35051261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soft Tissue Special Issue: Skeletal Muscle Tumors: A Clinicopathological Review.
    Kohashi K; Kinoshita I; Oda Y
    Head Neck Pathol; 2020 Mar; 14(1):12-20. PubMed ID: 31950473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in the Diagnosis of Pediatric Spindle Cell/Sclerosing Rhabdomyosarcoma.
    Chen S; Rudzinski ER; Arnold MA
    Surg Pathol Clin; 2020 Dec; 13(4):729-738. PubMed ID: 33183730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Spindle cell rhabdomyosarcoma in adults: a new entity in the spectrum of malignant mesenchymal tumors of soft tissues].
    Mentzel T
    Pathologe; 2010 Mar; 31(2):91-6. PubMed ID: 19997735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022. Emerging Bone and Soft Tissue Neoplasms in the Head and Neck Region.
    Xu B
    Head Neck Pathol; 2022 Mar; 16(1):158-167. PubMed ID: 35307771
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.